Charles Schwab’s BioNTech BNTX Stock Holding History

Charles Schwab’s Portfolio BNTX Stock Details BNTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$19.7M	Sell	211,762 -22,677	-10%	-$2.13M	﹤0.01%	1836
2026 Q1	$20.8M	Sell	234,439 -14,606	-6%	-$1.5M	﹤0.01%	1728
2025 Q4	$23.7M	Sell	249,045 -14,208	-5%	-$1.43M	﹤0.01%	1645
2025 Q3	$26M	Buy	263,253 +260	+0.1%	+$27.8K	﹤0.01%	1582
2025 Q2	$28M	Buy	262,993 +19,525	+8%	+$1.97M	﹤0.01%	1474
2025 Q1	$22.2M	Buy	243,468 +56,113	+30%	+$6.28M	﹤0.01%	1586
2024 Q4	$21.3M	Buy	187,355 +53,319	+40%	+$6.08M	﹤0.01%	1668
2024 Q3	$15.9M	Buy	134,036 +74,119	+124%	+$6.81M	﹤0.01%	1815
2024 Q2	$4.81M	Buy	+59,917	New	+$5.48M	﹤0.01%	2374

Other funds holding BNTX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Flossbach Von Storch Cologne, Germany $22.1B AUM 6.81% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

GSK plc London $602M AUM

Charles Schwab's BNTX Position: Q2 2026 in Review

Charles Schwab reduced its BioNTech (BNTX) stake by 9.7% in Q2 2026, selling an estimated $2.13M and leaving 211,762 shares worth $19.7M. The position accounts for ﹤0.01% of the portfolio, ranked #1836.

Charles Schwab first reported a position in BNTX in Q2 2024 and has held it in 9 quarters since. The position peaked at $28M in Q2 2025. 282 funds tracked by Wall St. Rank hold BNTX as of Q2 2026.

Charles Schwab held 211,762 shares of BioNTech worth $19.7M as of Q2 2026.
Charles Schwab sold 22,677 BioNTech shares in Q2 2026, an estimated $2.13M.
BioNTech made up ﹤0.01% of Charles Schwab's portfolio in Q2 2026, its #1836 holding.
Charles Schwab first reported a position in BioNTech in Q2 2024 and has held it in 9 quarters since.
Charles Schwab's BioNTech position peaked at $28M in Q2 2025.
282 funds tracked by Wall St. Rank held BioNTech as of Q2 2026.

Based on Charles Schwab's 13F filing for Q2 2026, filed 14 Aug 2026.